Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe
Open Access
- 1 July 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (9) , e212026
Abstract
The high cost of cancer medicines to patients and health systems globally is a public health challenge. Spending on cancer drugs is projected to grow to $100 billion in the US and $50 billion in Europe by 2022.1 The financial toxicity of costly cancer medicines may include medication nonadherence and negative patient outcomes.2-4 This challenge of paying for cancer therapies likely will be magnified in the coming years by the effect of the ongoing COVID-19 pandemic on individual finances and national economies.5Keywords
This publication has 17 references indexed in Scilit:
- Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017JAMA, 2019
- Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit ScoreJournal of Clinical Oncology, 2019
- Financial Toxicity in Adults With Cancer: Adverse Outcomes and NoncomplianceJournal of Oncology Practice, 2018
- ESMO-Magnitude of Clinical Benefit Scale version 1.1Annals of Oncology, 2017
- Public referendum on drug prices in the US: will it bring relief?BMJ, 2016
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments ReceivedJournal of Clinical Oncology, 2016
- Financial Toxicity of Cancer Care: It’s Time to InterveneJNCI: Journal of the National Cancer Institute, 2015
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2014
- How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers’ viewsAnnals of Oncology, 2014